Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0000950170-24-102919
Filing Date
2024-09-03
Accepted
2024-09-03 17:10:45
Documents
57
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 6-K asnd-20240630.htm   iXBRL 6-K 1807378
2 GRAPHIC img148560552_0.jpg GRAPHIC 18727
3 GRAPHIC img148560552_1.jpg GRAPHIC 105159
4 GRAPHIC img148560552_2.jpg GRAPHIC 48699
5 GRAPHIC img148560552_3.jpg GRAPHIC 16184
6 GRAPHIC img148560552_4.jpg GRAPHIC 18522
7 GRAPHIC img148560552_5.jpg GRAPHIC 192485
8 GRAPHIC img148560552_6.jpg GRAPHIC 24875
9 GRAPHIC img148560552_7.jpg GRAPHIC 19607
  Complete submission text file 0000950170-24-102919.txt   7489946

Data Files

Seq Description Document Type Size
10 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT asnd-20240630.xsd EX-101.SCH 1083742
59 EXTRACTED XBRL INSTANCE DOCUMENT asnd-20240630_htm.xml XML 1091207
Mailing Address TUBORG BOULEVARD 12 HELLERUP G7 DK-2900
Business Address TUBORG BOULEVARD 12 HELLERUP G7 DK-2900 45 70 22 22 44
Ascendis Pharma A/S (Filer) CIK: 0001612042 (see all company filings)

EIN.: 000000000 | State of Incorp.: G7 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-36815 | Film No.: 241274978
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)